When someone is facing surgery for medullary thyroid cancer, a key question is whether the cancer has already spread to the lymph nodes along the side of the neck. Knowing this helps surgeons decide how extensive the operation needs to be. A new analysis of existing research suggests a common pre-surgery blood test—measuring a hormone called calcitonin—might provide a useful clue.
The analysis pooled data from 951 patients across eight studies. It found that people whose cancer had spread to these lateral neck nodes had significantly higher calcitonin levels before surgery. When doctors used a threshold of 300 pg/mL, the test correctly identified 90% of cases with spread (sensitivity) and correctly ruled out spread in 62% of cases without it (specificity). The overall diagnostic accuracy was high.
This means the calcitonin test could serve as a practical, non-invasive indicator to guide more personalized surgical planning. It might supplement imaging scans, which can sometimes miss tiny metastases. However, this is a meta-analysis of observational diagnostic studies—it shows association, not causation. The analysis didn't report absolute patient numbers or track whether using the test actually led to better surgical outcomes. The evidence supports its use as a helpful piece of the diagnostic puzzle, not as a standalone decision-maker.